NEW YORK (GenomeWeb News) — Compugen and the Mayo Clinic plan to discover and validate biomarkers that could detect plaques linked to heart and brain diseases, the company said today.
 
Under the agreement, Compugen will retain exclusive commercialization rights to any products that result from the collaboration, which aims to find biomarkers for atherosclerotic plaques in coronary artery disease and in cerebrovascular disease.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.